Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Other hematologic neoplasm 2Gynecologic 2Thoracic 1Other 1Myeloid 1Dermatologic 1CNS 1

Conditions

Osteochondroma 1Non-alcoholic Fatty Liver Disease 1Nevus, Epithelioid and Spindle Cell 1Lung Neoplasms 1Hematologic Neoplasms 1Giant Cell Tumors 1Fibrosis 1Endometrial Hyperplasia 1Carcinoma, Lobular 1Carcinoma in Situ 1Barrett Esophagus 1

Interventions

Carboplatin 1167Cisplatin 889Pemetrexed 845pembrolizumab 622Paclitaxel 608Docetaxel 539Gemcitabine 428Radiotherapy 390Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 296durvalumab 264Drug Therapy 260osimertinib 236atezolizumab 224Radiosurgery 194Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 131Ipilimumab 129130-nm albumin-bound paclitaxel 124Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sampling Studies × Thoracic × Clear all
NCT05463796 2025-08-07

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Dana-Farber Cancer Institute

Recruiting
5,000 enrolled
GastrointestinalGynecologicOther hematologic neoplasmThoracic

Barrett Esophagus, Carcinoma in Situ, Endometrial Hyperplasia, Fibrosis, Giant Cell Tumors, Lung Neoplasms, Osteochondroma, Carcinoma, Lobular, Nevus, Epithelioid and Spindle Cell, Hematologic Neoplasms, Non-alcoholic Fatty Liver Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡